VIRI · Virios Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $21.87M | $3.53M | $1.73M | $8.07M | $194.0K |
| SG&A | $6.10M | $8.70M | $3.72M | $4.25M | $9.81M |
| Total Operating Expenses | $27.97M | $12.23M | $5.45M | $12.32M | $10.01M |
| D&A | $2.1K | $12.2K | - | - | - |
| Operating Income | ($27.97M) | ($12.23M) | ($5.45M) | ($12.32M) | ($10.01M) |
| Interest Expense | - | - | - | - | - |
| Income Tax | $221.1K | ($503) | - | - | - |
| Net Income | ($34.26M) | ($12.35M) | ($5.30M) | ($12.25M) | ($10.35M) |
| EPS - Basic | ($7.13) | ($12.52) | ($0.28) | ($1.11) | ($2.10) |
| EPS - Diluted | ($7.13) | ($12.52) | ($0.28) | ($1.11) | ($2.10) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6.52M | $14.85M | $3.32M | $7.03M | $14.01M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $760.9K | $1.23M | $111.9K | $573.2K | $353.9K |
| Current Assets | $8.43M | $16.54M | $4.17M | $8.37M | $15.78M |
| Total Assets | $90.17M | $94.31M | $4.17M | $8.37M | $15.78M |
| Current Liabilities | $3.06M | $3.18M | $358.5K | $1.04M | $1.28M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $15.27M | $30.03M | $358.5K | $1.04M | $1.28M |
| Stockholders' Equity | $74.90M | ($10.12M) | $3.81M | $7.33M | ($5.02M) |
| Retained Earnings | ($108.08M) | ($73.82M) | ($61.47M) | ($56.17M) | ($43.93M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($15.62M) | ($8.79M) | ($4.87M) | ($11.47M) | ($3.90M) |
| Investing Cash Flow | - | $3.76M | - | - | - |
| Financing Cash Flow | $7.28M | $16.70M | $1.16M | $4.49M | $33.38M |
| CapEx | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -38.0% | -13.1% | -127.1% | -146.3% | -65.6% |
| Return on equity | -45.7% | 122.0% | -139.1% | -167.2% | 206.2% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 |
| Quick ratio | 2.76 | 5.21 | 11.62 | 8.02 | 12.37 |
| Cash ratio | 2.13 | 4.67 | 9.25 | 6.74 | 10.98 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | - |
| Equity multiplier | 1.20 | -9.32 | 1.09 | 1.14 | -3.14 |
| Liabilities / Assets | 0.17 | 0.32 | 0.09 | 0.12 | 0.08 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -128.7% | -124.5% | 55.8% | -23.1% | - |
| Net income growth (YoY) | -177.4% | -133.2% | 56.8% | -18.4% | - |
| EPS growth (YoY) | 43.1% | -4371.4% | 74.8% | 47.1% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | - | - | -48.0% | - | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Virios Therapeutics against the 5 most active filers in the same SIC group.